Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $0.98, $0.08 better than the analyst estimate of $0.90. Revenue for the quarter came in at $354.9 million versus the consensus estimate of $354.91 million.

GUIDANCE:

Charles River Laboratories sees FY2016 EPS of $4.32-$4.45, versus the consensus of $4.34.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.